Phenylboronic acid-functionalized gelatin–oleic acid nanoparticles for high loading and efficient transdermal delivery of Celastrol towards the treatment of psoriasis
Systemic toxicity, poor aqueous solubility, and poorly cell permeable ability hindered the clinical application of Celastrol. In this study, we aimed to design and synthesize an amphiphilic conjugate to encapsulate Celastrol into micelles to improve its water solubility, cellular membrane penetration, improving the clinic translation potential of Celastrol for the treatment of psoriasis. For this purpose, we first synthesized gelatin and oleic acid conjugate (GOC-1), and then covalently bonded 4-(3-boronophenylamino)-4-oxobutanoic acid (BPOA) with GOC-1 to form a stable GOC-2 conjugate which can self-assemble into micelles in aqueous solution. Celastrol (Cel) was physically encapsulated into the core of GOCs micelles. The dynamic stability, particle size, drug release, zeta potential, drug-loading efficiency, and surface morphology of Cel/loaded GOCs nano-micelles were determined. In addition, cell viability, cellular uptake of Cel/loaded GOC-2, and skin permeation and in vivo anti-psoriasis effect of Cel-loaded GOC-2 were investigated. Our results have shown that Cel/loaded GOC-1 and Cel/loaded GOC-2 have spherical shapes with diameters of around 200–300 nm. Compared to GOC-1, GOC-2 micelles showed higher drug-loading efficiency and excellent permeation ability in vitro. Moreover, Cel/GOC-2 micelles reduced erythema and white scales on the dorsal skin of psoriatic mice. In conclusion, BPOA attached GOC nanoparticles as a Celastrol carrier not only increase its water solubility but also improve drug-loading efficiency and cell permeation ability, exhibiting superior anti-psoriatic effect than the commercially available tacrolimus. Our work is expected to provide a facile approach to prepare nanocarrier for Celastrol to improve the clinic translation potential of Celastrol. Graphical abstract Fabrication of Celastrol containing micelles and its Anti-psoriasis activity against IMQ induced mice model. Amphiphilic BPOA-modified gelatin–oleic conjugates (GOC-2) was synthesized and used as backbone to encapsulate Celastrol into self-assembled micelles. The synthesized Cel/GOC-2 micelles can completely dissolve in water as well biologically more effective. IMQ was used to induce psoriasis mouse models and then the Cel/GOC-2 micelles treatment carried out. GOC-2 micelles as a Celastrol improve drug-loading efficiency and cell permeation ability, exhibiting superior anti-psoriatic effect than the commercially available tacrolimus which improve therapeutic outcomes of Celastrol..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Macromolecular research - 31(2023), 11 vom: 05. Sept., Seite 1029-1042 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Jiangtao [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to The Polymer Society of Korea 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13233-023-00194-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053755006 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053755006 | ||
| 003 | DE-627 | ||
| 005 | 20231116064656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231116s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13233-023-00194-x |2 doi | |
| 035 | |a (DE-627)SPR053755006 | ||
| 035 | |a (SPR)s13233-023-00194-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Su, Jiangtao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phenylboronic acid-functionalized gelatin–oleic acid nanoparticles for high loading and efficient transdermal delivery of Celastrol towards the treatment of psoriasis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to The Polymer Society of Korea 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Systemic toxicity, poor aqueous solubility, and poorly cell permeable ability hindered the clinical application of Celastrol. In this study, we aimed to design and synthesize an amphiphilic conjugate to encapsulate Celastrol into micelles to improve its water solubility, cellular membrane penetration, improving the clinic translation potential of Celastrol for the treatment of psoriasis. For this purpose, we first synthesized gelatin and oleic acid conjugate (GOC-1), and then covalently bonded 4-(3-boronophenylamino)-4-oxobutanoic acid (BPOA) with GOC-1 to form a stable GOC-2 conjugate which can self-assemble into micelles in aqueous solution. Celastrol (Cel) was physically encapsulated into the core of GOCs micelles. The dynamic stability, particle size, drug release, zeta potential, drug-loading efficiency, and surface morphology of Cel/loaded GOCs nano-micelles were determined. In addition, cell viability, cellular uptake of Cel/loaded GOC-2, and skin permeation and in vivo anti-psoriasis effect of Cel-loaded GOC-2 were investigated. Our results have shown that Cel/loaded GOC-1 and Cel/loaded GOC-2 have spherical shapes with diameters of around 200–300 nm. Compared to GOC-1, GOC-2 micelles showed higher drug-loading efficiency and excellent permeation ability in vitro. Moreover, Cel/GOC-2 micelles reduced erythema and white scales on the dorsal skin of psoriatic mice. In conclusion, BPOA attached GOC nanoparticles as a Celastrol carrier not only increase its water solubility but also improve drug-loading efficiency and cell permeation ability, exhibiting superior anti-psoriatic effect than the commercially available tacrolimus. Our work is expected to provide a facile approach to prepare nanocarrier for Celastrol to improve the clinic translation potential of Celastrol. Graphical abstract Fabrication of Celastrol containing micelles and its Anti-psoriasis activity against IMQ induced mice model. Amphiphilic BPOA-modified gelatin–oleic conjugates (GOC-2) was synthesized and used as backbone to encapsulate Celastrol into self-assembled micelles. The synthesized Cel/GOC-2 micelles can completely dissolve in water as well biologically more effective. IMQ was used to induce psoriasis mouse models and then the Cel/GOC-2 micelles treatment carried out. GOC-2 micelles as a Celastrol improve drug-loading efficiency and cell permeation ability, exhibiting superior anti-psoriatic effect than the commercially available tacrolimus which improve therapeutic outcomes of Celastrol. | ||
| 650 | 4 | |a Celastrol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Micelles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-psoriasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Amphiphilic conjugate |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Lin, Na |4 aut | |
| 700 | 1 | |a You, Xiangyu |4 aut | |
| 700 | 1 | |a Dai, Heshuang |4 aut | |
| 700 | 1 | |a Rao, Meng |4 aut | |
| 700 | 1 | |a Ye, Lu |4 aut | |
| 700 | 1 | |a Ye, Fan |4 aut | |
| 700 | 1 | |a Cai, Le |4 aut | |
| 700 | 1 | |a Chen, Yuxin |4 aut | |
| 700 | 1 | |a Zhou, Gao |4 aut | |
| 700 | 1 | |a Guo, Xiaoxia |0 (orcid)0000-0003-0124-1378 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Macromolecular research |d Heidelberg : Springer, 2010 |g 31(2023), 11 vom: 05. Sept., Seite 1029-1042 |w (DE-627)SPR030952352 |w (DE-600)2537708-5 |x 2092-7673 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:11 |g day:05 |g month:09 |g pages:1029-1042 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13233-023-00194-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 11 |b 05 |c 09 |h 1029-1042 | ||